key: cord-0965363-2amh20vu authors: Munblit, Daniel; Bobkova, Polina; Spiridonova, Ekaterina; Shikhaleva, Anastasia; Gamirova, Aysylu; Blyuss, Oleg; Nekliudov, Nikita; Bugaeva, Polina; Andreeva, Margarita; DunnGalvin, Audrey; Comberiati, Pasquale; Apfelbacher, Christian; Genuneit, Jon; Avdeev, Sergey; Kapustina, Valentina; Guekht, Alla; Fomin, Victor; Svistunov, Andrey A.; Timashev, Peter; Subbot, Vladislav S.; Royuk, Valery V.; Drake, Thomas M.; Hanson, Sarah Wulf; Merson, Laura; Carson, Gail; Horby, Peter; Sigfrid, Louise; Scott, Janet T.; Semple, Malcolm G.; Warner, John O.; Vos, Theo; Olliaro, Piero; Glybochko, Petr; Butnaru, Denis title: Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19 date: 2021-08-12 journal: Clin Exp Allergy DOI: 10.1111/cea.13997 sha: 4a5af7b0edb69b51a3108a23dce188a65f0bdb83 doc_id: 965363 cord_uid: 2amh20vu BACKGROUND: The long‐term sequalae of COVID‐19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID‐19 and assessed potential risk factors. METHODS: Data were collected from patients discharged from 4 hospitals in Moscow, Russia between 8 April and 10 July 2020. Participants were interviewed via telephone using an ISARIC Long‐term Follow‐up Study questionnaire. RESULTS: 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post‐discharge. COVID‐19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). CONCLUSIONS: Almost half of adults admitted to hospital due to COVID‐19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed a significant burden on health services and society worldwide. There have now been well over 100 million coronavirus disease 2019 (COVID-19) cases reported with a mortality rate of around 2.2%globally. 1 The acute presentation of COVID-19 has now been well investigated, with fever, cough, shortness of breath and anosmia among the most commonly reported symptoms. [2] [3] [4] It has become evident that a substantial proportion of people experience ongoing symptoms including fatigue and muscle weakness, joint and muscle pain, and breathlessness, months after the acute phase of COVID-19. [5] [6] [7] This phenomenon is now commonly referred to as Long COVID but has also been described as post-COVID syndrome, Post-Acute Sequelae of SARS-CoV-2 infection (PASC), the post-COVID-19 condition 8 or patients have been labelled COVID long-haulers. 9, 10 There is still a paucity of long-term follow-up data, which means we have limited knowledge of the full range of symptoms, duration of disease and potential risk factors. Recently published data from China describing long-term consequences of show that 76% of previously hospitalized adult patients have at least one symptom 6 months after acute infection. 6 In a UK registry study of 47,780 previously hospitalized adults, 29.4% were readmitted and 12.3% died after initial discharge with multi-organ dysfunction. 11 There is an urgent need for accurate long-term follow-up of COVID-19 patients, 7 to inform future management plans and address the devastating impacts of this condition on the quality of life (QoL) of people affected. This observational cohort study aimed to investigate the incidence of long-term consequences in adults previously hospitalized for COVID-19 and to assess risk factors for Long COVID in Moscow, Russia. We used the standardized follow-up data collection protocol of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). This is a longitudinal cohort study of patients with suspected or confirmed COVID-19 infection admitted to Sechenov University Hospital Network (four tertiary hospitals) in Moscow, Russia. We collected the follow-up data between 2 December 2020 and 14 January 2021 from patients discharged between 8 April 2020 and July, 2020. We included adult patients (≥18 years of age), with either reverse transcriptase polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection and clinically confirmed infection, when the laboratory testing result is negative, inconclusive or unavailable. The acute phase data, including comorbidities and disease severity, were extracted from electronic medical records (EMR) and the Local Health Information System (HIS) at the host institution using the modified and translated ISARIC WHO Clinical Characterisation protocol (CCP). 12 Details of the acute phase data collection are described elsewhere. 3 We used REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at Sechenov University and Microsoft Excel (Microsoft Corp) for data collection, storage and management. 11, 12 The baseline characteristics, including demographics, symptoms on admission and comorbidities, had been extracted from EMRs and entered into REDCap previously. The acute disease severity was stratified in accordance with Arnold et al. 10 by a three-category scale based on the degree of required supportive care during hospital stay: mild (no supplementary oxygen or intensive care), moderate (supplementary oxygen during hospitalization) and severe (need for non-invasive respiratory modalities (NIV), invasive mechanical ventilation (IMV) and/or admission to intensive care unit (ICU)). A difference of 10 points at EQ-VAS defined relevant change in the health status. 4 All comorbidities were reported by the patients and/or family members at the time of the hospital admission and subsequently double checked during the follow-up telephone interview. For the purpose of this study, we defined "persistent symptoms" (PS) as symptoms present since hospital discharge only. • 6-8 months after hospital discharge, around a half of patients with Covid-19 experienced persistent symptoms • Chronic fatigue and respiratory problems were the commonest persistent symptoms, with 11.3% having multisystem involvement • Female sex was associated with higher risk of persistent symptoms PS present at the time of follow-up were categorized into respiratory, gastrointestinal, dermatological, chronic fatigue, neurological, mood and behaviour, sensory (Table S1 ). Symptom categorization was based on previously published literature 14, 15 and international expert group discussions. Descriptive statistics were calculated for baseline characteristics. Continuous variables were summarized as median (with interquartile range) and categorical variables as frequency (percentage). The chisquared test or Fisher's exact test was used for testing differences in proportions between groups. The Wilcoxon rank-sum test was used for testing the hypotheses about differences in means between the groups. We performed multivariable logistic regression to investigate associations of demographic characteristics, comorbidities and severity of acute phase COVID-19 with PS categories presence at the time of the follow-up interview. To enhance the robustness of the effect estimates, only comorbidities that were present in at least 3% of the cohort were included in the modelling. Primary analysis was performed using the full data set, whereas sensitivity analysis included only a subset of people with RT-PCR confirmed SARS-CoV-2 infection (ICD U07.1). We have previously found no significant differences in clinical signs, symptoms, laboratory test results and risk factors for in-hospital mortality between clinically diagnosed patients and patients with positive RT-PCR. 3 Therefore, primary analysis was performed using the full cohort. Robustness of findings was then investigated via sensitivity analysis which included only a subset with confirmed SARS-CoV-2 infection. We have not performed any imputation for missing data. Venn diagrams were used to present the coexistence of the five most common persistent symptoms. Two-sided p-values were reported for all statistical tests, a pvalue below 0.05 was considered to be statistically significant. Statistical analysis was performed using R version 3.5.1. As outlined in Figure 1 , out of 5,040 patients hospitalized with suspected COVID-19 to the hospitals before 10 July 2020, 4,755 were discharged alive or transferred to another facility. Out of 4,019 patients with accurate contact information available, 2,649 were available for follow-up (response rate 68.5%), 2,649 of whom had no missing baseline data in the electronic database and were included in the analysis. Of the 3,868 patients with contact information available 52 (1.3%) died after the hospital discharge. Analysis of the non-response data was performed and Table S3 . Although many patients had PS since discharge, some participants reported at least one symptom of a differing duration during follow-up interview; 285 (10.8%) had experienced these symptoms for 3 to 6 months, 179 (6.8%) between 2 and 3 months, 157 (5.9%) between 1 and 2 months, 103 (3.9%) between 2 and 4 weeks and 140 (5.3%) between 1 and 2 weeks, respectively. The duration of the ten common symptoms at the time of the follow-up is shown in Figure S1 . Risk factors for all categories were assessed. In multivariable regression analysis, female sex was a predictor of "any" PS category with an Table 2 , and forest plots are available as supplementary material. (Table S4) . patients reported at least one PS, with chronic fatigue and respiratory problems being the most frequent PS categories. One in ten patients reported multisystem impacts with three or more categories of PS symptoms present at follow-up. PS were experienced by both sexes, with a higher risk amongst women. Pre-existing chronic pulmonary disease was associated with chronic fatigue, and asthma with a higher risk of neurological symptoms and mood and behaviour problems. Other studies of previously hospitalized and non-hospitalized COVID-19 patients reported presence of short-and long-term symptoms. 16 Female sex was significantly associated with an increased risk of PS, regardless of symptom category, reflecting previous findings 6 and digital App 19 studies. Chronic pulmonary disease was a risk factor for the development of chronic fatigue. An association between chronic pulmonary disease and severe acute COVID-19 was found in many F I G U R E 5 Multivariable logistic regression model. Odds ratios and 95% CIs for "Chronic fatigue" category of persistent symptoms at the time of follow-up. Abbreviation: CI, confidence interval. (A) primary analysis (age, sex, comorbidities, severity and RT-PCR were included as potential risk factors); (B) sensitivity analysis (performed in a subgroup of RT-PCR positive patients only) Risk factors significantly associated with the different categories of persistent symptoms in the primary (age, sex, comorbidities, severity and RT-PCR were included as potential risk factors) and sensitivity (performed in a subgroup of RT-PCR positive patients only) multivariable regression analyses Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; RT-PCR "+," real-time polymerase chain reaction confirmed SARS-CoV-2 infection. *The assessment of robustness is based on the magnitude, direction and/or statistical significance of the estimates. † Number of patients with at least one persistent symptom from this category. Statistically significant associations are presented in bold. studies, 20 but it has not been previously reported as a risk factor for COVID-19 sequelae. The presence of chronic pulmonary disease has been previously associated with chronic fatigue syndrome. 21 The pandemic also had a significant adverse impact on care and support for patients with chronic pulmonary conditions, including a reduction in face-to-face clinic availability, lack of access to pulmonary rehabilitation sessions and hospital care during an exacerbation due to fear of COVID-19 exposure. 22 The causality cannot be determined and we are unable to conclude if lack of follow-up and involvement in rehabilitation programmes for chronic pulmonary conditions was the cause of ongoing symptoms. Future research should investigate COVID-19 consequences in this group of patients in greater detail. Data from the COVID Symptom Study app in the UK suggested that asthma is a risk factor for post-COVID condition. 23 However, it did not separate ongoing respiratory symptoms which may have been due to incitement of the pre-existing asthma from those in other systems. We found that asthma was associated with an in- Patients with all categories of PS reported significantly lower health state when compared with symptom-free patients. They also considered the health state to be lower than before the COVID-19 episode. This is consistent with previous reports from different countries. 5, 6, 27 This finding points to the multi-factorial adverse effects of COVID-19 and to the need for wide ranging and longer term support. A major strength of this study is the use of pre-positioned data col- Future studies should focus on patients with multisystem involvement and longer follow-up of a large sample will allow for a better understanding of COVID-19 sequelae and help with the phenotype recognition. Investigation of immunological aspects of the association between asthma and several long-COVID outcomes may identify mechanisms and therapeutic targets for therapy to mitigate adverse consequences. We thank RFBR, grant 20-04-60063 for supporting the work. We would also like to thank UK Embassy in Moscow for providing a An interactive web-based dashboard to track COVID-19 in real time Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study StopCOVID cohort: an observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. medRxiv Gemelli against C-P-ACSG. persistent symptoms in patients after acute COVID-19 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Salima Deunezhewa 1 , Khalisa Elifkhanova 1 , Anastasia Ezhova 1 , Yulia Filippova 1 , Aleksandra Frolova 1 , Julia Ganieva 1 , Anastasia Gorina 1 , Yulia Kalan 1 2 Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine Characterising long-term covid-19: a rapid living systematic review. medRxiv Long covid: WHO calls on countries to offer patients more rehabilitation Meeting the challenge of long COVID Facing up to long COVID. The Lancet Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study COVID-19 core case report form acute respiratory infection clinical characterisation data tool Global COVID-19 Clinical Platform Case Report Form (CRF) for Post COVID condition (Post. COVID-19 CRF) Characterizing long COVID in an International cohort: 7 months of symptoms and their impact Management of post-acute covid-19 in primary care High-dimensional characterization of postacute sequelae of COVID-19 Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19 Attributes and predictors of long COVID The impact of COPD and smoking history on the severity of COVID-19: A systemic review and metaanalysis Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease COVID-19 and COPD Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 Eosinophilia in asthma patients is protective against severe COVID-19 illness Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19 The data that support the findings of this study are available from the corresponding author, DM, upon reasonable request.